Ethambutol Tablets

[11 November 2015]

Products Affected - Description

Ethambutol tablet, Akorn
400 mg, 90 count (NDC 61748-0014-09)
400 mg, 100 count (NDC 61748-0014-01)
400 mg, unit-dose 100 count (NDC 61748-0014-11)
400 mg, 1000 count (NDC 61748-0014-10)
Ethambutol tablets, Teva
400 mg tablets, 100 count (NDC 00555-0923-02)

Reason for the Shortage

  • Akorn acquired VersaPharm, Inc. in 2014.
  • Akorn could not provide a reason for the shortage.
  • X-Gen could not provide a reason for the shortage.
  • G&W Laboratories discontinued ethambutol tablets in mid-April 2013.

Available Products

Myambutol tablet, X-Gen
400 mg, 100 count (NDC 68850-0012-02)
400 mg, 100 count (NDC 68850-0012-01)
Ethambutol tablet, Akorn
100 mg, 100 count (NDC 61748-0011-01)
400 mg, 60 count (NDC 61748-0014-06)
Ethambutol tablet, Lupin
100 mg, 100 count (NDC 68180-0280-01)
400 mg, 100 count (NDC 68180-0281-01)

Estimated Resupply Dates

  • Akorn has ethambutol 400 mg tablets in 90 count, 100 count, 100 count unit-dose, and 1000 count sizes on back order and the company cannot estimate a release date.
  • Teva has had ethambutol 400 mg tablets temporarily unavailable since December 2013.

Related Shortages


November 11, September 17, August 19, July 17, May 6, 2015, University of Utah, Drug Information Service. Copyright 2015, Drug Information Service, University of Utah, Salt Lake City, UT.


This information is provided through the support of Novation to ASHP solely as a service to its members, which shall not use this information for their further commercial use. The content was prepared by the Drug Information Center of University of Utah. Novation, ASHP, and the University of Utah make no representations or warranties, express or implied, including, but not limited to, any implied warranty of merchantability and/or fitness for a particular purpose, which respect to such information, and specifically disclaim all such warranties. Users of this information are advised that decisions regarding the use of drugs and drug therapies are complex medical decisions and that in using this information, each user must exercise his or her own independent professional judgment. Neither Novation, ASHP nor the University of Utah assumes any liability for persons administering or receiving drugs or other medical care in reliance upon this information, or otherwise in connection with this bulletin. Neither Novation, ASHP nor University of Utah endorses or recommends the use of any drug.

« Back to Drug Shortage Product Bulletins

Advocacy Activity
Get the latest updates on ASHP's advocacy activity on drug shortages.